Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors

Bioengineering of the factor VIII (FVIII) molecule has led to the production of variants that overcome poor secretion and/or rapid inactivation. We tested six modified FVIII variants for in vivo efficacy by expressing them from helper-dependent adenoviral (HD-Ad) vectors. We constructed a wild-type...

Full description

Saved in:
Bibliographic Details
Published in:Molecular therapy 2007-12, Vol.15 (12), p.2080-2087
Main Authors: Cerullo, Vincenzo, Seiler, Michael P, Mane, Viraj, Cela, Racel, Clarke, Christian, Kaufman, Randal J, Pipe, Steven W, Lee, Brendan
Format: Article
Language:English
Subjects:
Adenoviridae - genetics
Animals
Bioengineering
Drug dosages
Factor VIII - genetics
Factor VIII - immunology
Factor VIII - therapeutic use
Gene therapy
Genetic Engineering
Genetic Vectors
HeLa Cells
Hemophilia
Hemophilia A - therapy
Humans
Immunology
Mice
Phenotype
Protein expression
Proteins
Toxicity
Vectors (Biology)
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c428t-bb755e9a7cfb19a45124da06c127b12d23798f57ad509d9141aa6c309bc5e3ba0
cites cdi_FETCH-LOGICAL-c428t-bb755e9a7cfb19a45124da06c127b12d23798f57ad509d9141aa6c309bc5e3ba0
container_end_page 2087
container_issue 12
container_start_page 2080
container_title Molecular therapy
container_volume 15
creator Cerullo, Vincenzo
Seiler, Michael P
Mane, Viraj
Cela, Racel
Clarke, Christian
Kaufman, Randal J
Pipe, Steven W
Lee, Brendan
description Bioengineering of the factor VIII (FVIII) molecule has led to the production of variants that overcome poor secretion and/or rapid inactivation. We tested six modified FVIII variants for in vivo efficacy by expressing them from helper-dependent adenoviral (HD-Ad) vectors. We constructed a wild-type (WT) variant, a B-domain-deleted (BDD) variant, a point mutant for improved secretion (F309S), a variant with a partial B-domain deletion for improved secretion (N6), a combination of the point mutant and partial BDD variant (F309N6), and an inactivation-resistant (IR8) FVIII variant. All the constructs expressed functional protein after injection of high-dose HD-Ad. Activity ranged from 20 to 50% with WT, to ∼100% with the N6 and F309N6 variants. Interestingly, mice treated with N6 showed long-term FVIII activity and phenotypic correction for up to 74 weeks, with low anti-FVIII antibody titer. Importantly, the N6 variant was therapeutically efficacious even after a 50% reduction of viral dose, thereby indicating that transgene modification itself can improve the dose efficacy of HD-Ad. This finding is significant, because dose efficacy is a key factor in clinical application. In summary, bioengineering of the FVIII molecule may be an effective approach to improving the safety, immunogenicity, and efficacy of HD-Ad gene therapy in hemophilia A (HA).
doi_str_mv 10.1038/sj.mt.6300308
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68532378</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1525001616327216</els_id><sourcerecordid>68532378</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-bb755e9a7cfb19a45124da06c127b12d23798f57ad509d9141aa6c309bc5e3ba0</originalsourceid><addsrcrecordid>eNp1kUGL1DAUx4Mo7rp69KgEBG8dk7ZJm-Mw6-4WVrzoXEOavGqGNqlJOrDfwI9tygy7sOAlefB-75fw_gi9p2RDSdV-iYfNlDa8IqQi7Qt0SVnJCkLK-uVjTfkFehPjIVeUCf4aXdCmrVvBySX6u_MhgE7WO-wH_G0J1gG-g8nPv-1oFd5i5QzupmlxfvS_rFYjvrbDAAGchrgO3SidfMD7ruvwXgWrXIr4GkZ7zJDB_UP2jTOEwsAMzoBLeJtPf7Qhy_awTse36NWgxgjvzvcV-nnz9cfurrj_ftvttveFrss2FX3fMAZCNXroqVA1o2VtFOGalk1PS1NWjWgH1ijDiDCC1lQprisies2g6hW5Qp9P3jn4PwvEJCcbNYyjcuCXKHnLqixpM_jpGXjwS3D5b5I2ouS0bhnPVHGidPAxBhjkHOykwoOkRK4ByXiQU5LngDL_8Wxd-gnME31OJAMfToBTaQnwCDwJmlMf8pKOFoKM2q5RGLvmKI23_3n6H8Ltqb8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1792614856</pqid></control><display><type>article</type><title>Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors</title><creator>Cerullo, Vincenzo ; Seiler, Michael P ; Mane, Viraj ; Cela, Racel ; Clarke, Christian ; Kaufman, Randal J ; Pipe, Steven W ; Lee, Brendan</creator><creatorcontrib>Cerullo, Vincenzo ; Seiler, Michael P ; Mane, Viraj ; Cela, Racel ; Clarke, Christian ; Kaufman, Randal J ; Pipe, Steven W ; Lee, Brendan</creatorcontrib><description>Bioengineering of the factor VIII (FVIII) molecule has led to the production of variants that overcome poor secretion and/or rapid inactivation. We tested six modified FVIII variants for in vivo efficacy by expressing them from helper-dependent adenoviral (HD-Ad) vectors. We constructed a wild-type (WT) variant, a B-domain-deleted (BDD) variant, a point mutant for improved secretion (F309S), a variant with a partial B-domain deletion for improved secretion (N6), a combination of the point mutant and partial BDD variant (F309N6), and an inactivation-resistant (IR8) FVIII variant. All the constructs expressed functional protein after injection of high-dose HD-Ad. Activity ranged from 20 to 50% with WT, to ∼100% with the N6 and F309N6 variants. Interestingly, mice treated with N6 showed long-term FVIII activity and phenotypic correction for up to 74 weeks, with low anti-FVIII antibody titer. Importantly, the N6 variant was therapeutically efficacious even after a 50% reduction of viral dose, thereby indicating that transgene modification itself can improve the dose efficacy of HD-Ad. This finding is significant, because dose efficacy is a key factor in clinical application. In summary, bioengineering of the FVIII molecule may be an effective approach to improving the safety, immunogenicity, and efficacy of HD-Ad gene therapy in hemophilia A (HA).</description><identifier>ISSN: 1525-0016</identifier><identifier>EISSN: 1525-0024</identifier><identifier>DOI: 10.1038/sj.mt.6300308</identifier><identifier>PMID: 17848960</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenoviridae - genetics ; Animals ; Bioengineering ; Drug dosages ; Factor VIII - genetics ; Factor VIII - immunology ; Factor VIII - therapeutic use ; Gene therapy ; Genetic Engineering ; Genetic Vectors ; HeLa Cells ; Hemophilia ; Hemophilia A - therapy ; Humans ; Immunology ; Mice ; Phenotype ; Protein expression ; Proteins ; Toxicity ; Vectors (Biology)</subject><ispartof>Molecular therapy, 2007-12, Vol.15 (12), p.2080-2087</ispartof><rights>2007 The American Society of Gene Therapy</rights><rights>Copyright Nature Publishing Group Dec 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-bb755e9a7cfb19a45124da06c127b12d23798f57ad509d9141aa6c309bc5e3ba0</citedby><cites>FETCH-LOGICAL-c428t-bb755e9a7cfb19a45124da06c127b12d23798f57ad509d9141aa6c309bc5e3ba0</cites></display><links><openurl>$$Topenurl_article</openurl><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>783</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17848960$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cerullo, Vincenzo</creatorcontrib><creatorcontrib>Seiler, Michael P</creatorcontrib><creatorcontrib>Mane, Viraj</creatorcontrib><creatorcontrib>Cela, Racel</creatorcontrib><creatorcontrib>Clarke, Christian</creatorcontrib><creatorcontrib>Kaufman, Randal J</creatorcontrib><creatorcontrib>Pipe, Steven W</creatorcontrib><creatorcontrib>Lee, Brendan</creatorcontrib><title>Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors</title><title>Molecular therapy</title><addtitle>Mol Ther</addtitle><description>Bioengineering of the factor VIII (FVIII) molecule has led to the production of variants that overcome poor secretion and/or rapid inactivation. We tested six modified FVIII variants for in vivo efficacy by expressing them from helper-dependent adenoviral (HD-Ad) vectors. We constructed a wild-type (WT) variant, a B-domain-deleted (BDD) variant, a point mutant for improved secretion (F309S), a variant with a partial B-domain deletion for improved secretion (N6), a combination of the point mutant and partial BDD variant (F309N6), and an inactivation-resistant (IR8) FVIII variant. All the constructs expressed functional protein after injection of high-dose HD-Ad. Activity ranged from 20 to 50% with WT, to ∼100% with the N6 and F309N6 variants. Interestingly, mice treated with N6 showed long-term FVIII activity and phenotypic correction for up to 74 weeks, with low anti-FVIII antibody titer. Importantly, the N6 variant was therapeutically efficacious even after a 50% reduction of viral dose, thereby indicating that transgene modification itself can improve the dose efficacy of HD-Ad. This finding is significant, because dose efficacy is a key factor in clinical application. In summary, bioengineering of the FVIII molecule may be an effective approach to improving the safety, immunogenicity, and efficacy of HD-Ad gene therapy in hemophilia A (HA).</description><subject>Adenoviridae - genetics</subject><subject>Animals</subject><subject>Bioengineering</subject><subject>Drug dosages</subject><subject>Factor VIII - genetics</subject><subject>Factor VIII - immunology</subject><subject>Factor VIII - therapeutic use</subject><subject>Gene therapy</subject><subject>Genetic Engineering</subject><subject>Genetic Vectors</subject><subject>HeLa Cells</subject><subject>Hemophilia</subject><subject>Hemophilia A - therapy</subject><subject>Humans</subject><subject>Immunology</subject><subject>Mice</subject><subject>Phenotype</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Toxicity</subject><subject>Vectors (Biology)</subject><issn>1525-0016</issn><issn>1525-0024</issn><fulltext>false</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNp1kUGL1DAUx4Mo7rp69KgEBG8dk7ZJm-Mw6-4WVrzoXEOavGqGNqlJOrDfwI9tygy7sOAlefB-75fw_gi9p2RDSdV-iYfNlDa8IqQi7Qt0SVnJCkLK-uVjTfkFehPjIVeUCf4aXdCmrVvBySX6u_MhgE7WO-wH_G0J1gG-g8nPv-1oFd5i5QzupmlxfvS_rFYjvrbDAAGchrgO3SidfMD7ruvwXgWrXIr4GkZ7zJDB_UP2jTOEwsAMzoBLeJtPf7Qhy_awTse36NWgxgjvzvcV-nnz9cfurrj_ftvttveFrss2FX3fMAZCNXroqVA1o2VtFOGalk1PS1NWjWgH1ijDiDCC1lQprisies2g6hW5Qp9P3jn4PwvEJCcbNYyjcuCXKHnLqixpM_jpGXjwS3D5b5I2ouS0bhnPVHGidPAxBhjkHOykwoOkRK4ByXiQU5LngDL_8Wxd-gnME31OJAMfToBTaQnwCDwJmlMf8pKOFoKM2q5RGLvmKI23_3n6H8Ltqb8</recordid><startdate>20071201</startdate><enddate>20071201</enddate><creator>Cerullo, Vincenzo</creator><creator>Seiler, Michael P</creator><creator>Mane, Viraj</creator><creator>Cela, Racel</creator><creator>Clarke, Christian</creator><creator>Kaufman, Randal J</creator><creator>Pipe, Steven W</creator><creator>Lee, Brendan</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20071201</creationdate><title>Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors</title><author>Cerullo, Vincenzo ; Seiler, Michael P ; Mane, Viraj ; Cela, Racel ; Clarke, Christian ; Kaufman, Randal J ; Pipe, Steven W ; Lee, Brendan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-bb755e9a7cfb19a45124da06c127b12d23798f57ad509d9141aa6c309bc5e3ba0</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adenoviridae - genetics</topic><topic>Animals</topic><topic>Bioengineering</topic><topic>Drug dosages</topic><topic>Factor VIII - genetics</topic><topic>Factor VIII - immunology</topic><topic>Factor VIII - therapeutic use</topic><topic>Gene therapy</topic><topic>Genetic Engineering</topic><topic>Genetic Vectors</topic><topic>HeLa Cells</topic><topic>Hemophilia</topic><topic>Hemophilia A - therapy</topic><topic>Humans</topic><topic>Immunology</topic><topic>Mice</topic><topic>Phenotype</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Toxicity</topic><topic>Vectors (Biology)</topic><toplevel>peer_reviewed</toplevel><creatorcontrib>Cerullo, Vincenzo</creatorcontrib><creatorcontrib>Seiler, Michael P</creatorcontrib><creatorcontrib>Mane, Viraj</creatorcontrib><creatorcontrib>Cela, Racel</creatorcontrib><creatorcontrib>Clarke, Christian</creatorcontrib><creatorcontrib>Kaufman, Randal J</creatorcontrib><creatorcontrib>Pipe, Steven W</creatorcontrib><creatorcontrib>Lee, Brendan</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>no_fulltext</fulltext></delivery><addata><au>Cerullo, Vincenzo</au><au>Seiler, Michael P</au><au>Mane, Viraj</au><au>Cela, Racel</au><au>Clarke, Christian</au><au>Kaufman, Randal J</au><au>Pipe, Steven W</au><au>Lee, Brendan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors</atitle><jtitle>Molecular therapy</jtitle><addtitle>Mol Ther</addtitle><date>2007-12-01</date><risdate>2007</risdate><volume>15</volume><issue>12</issue><spage>2080</spage><epage>2087</epage><pages>2080-2087</pages><issn>1525-0016</issn><eissn>1525-0024</eissn><abstract>Bioengineering of the factor VIII (FVIII) molecule has led to the production of variants that overcome poor secretion and/or rapid inactivation. We tested six modified FVIII variants for in vivo efficacy by expressing them from helper-dependent adenoviral (HD-Ad) vectors. We constructed a wild-type (WT) variant, a B-domain-deleted (BDD) variant, a point mutant for improved secretion (F309S), a variant with a partial B-domain deletion for improved secretion (N6), a combination of the point mutant and partial BDD variant (F309N6), and an inactivation-resistant (IR8) FVIII variant. All the constructs expressed functional protein after injection of high-dose HD-Ad. Activity ranged from 20 to 50% with WT, to ∼100% with the N6 and F309N6 variants. Interestingly, mice treated with N6 showed long-term FVIII activity and phenotypic correction for up to 74 weeks, with low anti-FVIII antibody titer. Importantly, the N6 variant was therapeutically efficacious even after a 50% reduction of viral dose, thereby indicating that transgene modification itself can improve the dose efficacy of HD-Ad. This finding is significant, because dose efficacy is a key factor in clinical application. In summary, bioengineering of the FVIII molecule may be an effective approach to improving the safety, immunogenicity, and efficacy of HD-Ad gene therapy in hemophilia A (HA).</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>17848960</pmid><doi>10.1038/sj.mt.6300308</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext no_fulltext
identifier ISSN: 1525-0016
ispartof Molecular therapy, 2007-12, Vol.15 (12), p.2080-2087
issn 1525-0016
1525-0024
language eng
recordid cdi_proquest_miscellaneous_68532378
source
subjects Adenoviridae - genetics
Animals
Bioengineering
Drug dosages
Factor VIII - genetics
Factor VIII - immunology
Factor VIII - therapeutic use
Gene therapy
Genetic Engineering
Genetic Vectors
HeLa Cells
Hemophilia
Hemophilia A - therapy
Humans
Immunology
Mice
Phenotype
Protein expression
Proteins
Toxicity
Vectors (Biology)
title Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-16T06%3A04%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correction%20of%20Murine%20Hemophilia%20A%20and%20Immunological%20Differences%20of%20Factor%20VIII%20Variants%20Delivered%20by%20Helper-dependent%20Adenoviral%20Vectors&rft.jtitle=Molecular%20therapy&rft.au=Cerullo,%20Vincenzo&rft.date=2007-12-01&rft.volume=15&rft.issue=12&rft.spage=2080&rft.epage=2087&rft.pages=2080-2087&rft.issn=1525-0016&rft.eissn=1525-0024&rft_id=info:doi/10.1038/sj.mt.6300308&rft_dat=%3Cproquest_cross%3E68532378%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c428t-bb755e9a7cfb19a45124da06c127b12d23798f57ad509d9141aa6c309bc5e3ba0%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1792614856&rft_id=info:pmid/17848960&rfr_iscdi=true